| 17-1493 | Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS Metastasis | Open (affiliates only) |
| A011502-CIRB-REX | Rex_Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial | Open (affiliates only) |
| A031102-CIRB | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
| Open |
| AGCT1531 | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | Open |
| AMGEN359 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of
Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of
Recurrence (D-CARE) | Open (affiliates only) |
| AMGEN482 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With
Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly
Diagnosed Multiple Myeloma | Open (affiliates only) |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| ASG-22CE-13-2 | A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 | Open |
| BMT-CTN-1506 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | Open |
| CP-MGD014-01 | A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | Open |
| DELETETEST4 | A four part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine,or Concurrent BKM120 and Capecitabine and Trastuzumab, in Patients with Metastatic Colon Cancer (Test4) | Open |
| ETCTN9767-CIRB | An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation. | Open |
| H3B-6545-A001-101 | A Phase I-II multicenter, open label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, in women with locally advanced or metastatic estrogen receptor-positive, HER2 negative breast cancer | Open |
| IMMU-132-05 | An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments | Open |
| INCB-18424-365 | A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3) | Open |
| LCCC1725 | A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab together with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma | Open |
| NCI-10139-CIRB | A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma | Open |
| ONC012 | A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer | Open |
| PEVONEDISTAT-3001 | Pevonedistat-3001 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia | Open |
| RTOG1008 | A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
| Open |
| SGN22E-002 | A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer | Open |
| TCD14079 | SAR650984 TCD14079 isatuximab A Phase 1b Study of SAR650984 (isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | Open |